Video

Dr. Bekaii-Saab on the Addition of Atezolizumab to Capecitabine/Bevacizumab in MSS mCRC

Tanios S. Bekaii-Saab, MD, FACP, discusses the results of the phase II BACCI trial evaluating the addition of atezolizumab to capecitabine plus bevacizumab versus capecitabine/bevacizumab plus placebo in patients with microsatellite stable metastatic colorectal cancer.

Tanios S. Bekaii-Saab, MD, FACP, medical oncologist, medical director, Cancer Clinical Research Office, vice chair and section chief, Medical Oncology, Department of Internal Medicine, Mayo Clinic, discusses the results of the phase II BACCI trial evaluating the addition of atezolizumab (Tecentriq) to capecitabine plus bevacizumab (Avastin) versus capecitabine/bevacizumab plus placebo in patients with microsatellite stable (MSS) metastatic colorectal cancer.

In the trial, 133 patients were randomized 2:1 to receive capecitabine/bevacizumab/placebo (n = 46; arm A) or capecitabine/bevacizumab/atezolizumab (n = 82; arm B). Patients enrolled on the trial had progressed on fluorouracil, oxaliplatin, irinotecan, bevacizumab, and anti-EGFR therapy. Prior treatment with PD-1/PD-L1 inhibitors was not allowed. The primary endpoint of the trial was progression-free survival (PFS).

The study was reported to have reached its prespecified primary endpoint at the 2019 ESMO Congress. The addition of atezolizumab to capecitabine/bevacizumab led to a significantly longer PFS. Specifically, in patients with MSS disease, the hazard ratio for PFS was 0.67 (0.44-1.03), which was very impressive, says Bekaii-Saab. With further analysis, Bekaii-Saab believes that the combination will eventually be evaluated in a phase III randomized trial.

Related Videos
Tiago Biachi, MD, PhD
Dr Girard on De Novo and Acquired Resistance Alterations in HER2-Altered NSCLC
Haley M. Hill, PA-C, discusses preliminary data for zenocutuzumab in NRG1 fusion–positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses how physician assistants aid in treatment planning for NRG1-positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses DNA vs RNA sequencing for genetic testing in non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses current approaches and treatment challenges in NRG1-positive non–small cell lung cancer and pancreatic cancer.
Elias Jabbour, MD
Daniel DeAngelo, MD, PhD
Douglas W. Sborov, MD, MS
Meletios (Thanos) Dimopoulos, MD, professor, therapeutics, Hematology Oncology, National and Kapodistrian University of Athens School of Medicine